Antihistamines News and Research

RSS

Schering-Ploug will return more than $9 million to the Texas Medicaid program for the company’s fraudulent reporting of prices for drug Claritin

Texas Attorney General Greg Abbott has announced a settlement among Texas and other states with pharmaceutical giant Schering-Plough Inc. that will return more than $9 million to the Texas Medicaid program for the company’s fraudulent reporting of prices for the antihistamine drug Claritin.

2 Aug 2004

Schering Plough to reimburse Washington's Medicaid program $3.57 million in Claritin case

Pharmaceutical manufacturer Schering Plough will reimburse Washington's Medicaid program $3.57 million in a nationwide settlement of allegations the drug maker failed to offer state Medicaid programs its best price for the popular antihistamine drug Claritin.

31 Jul 2004

Research into hay fever and temperature of the nose rises helps determine how reliable and effective anti-allergic agents are

In an attack of hay fever, the temperature of the nose rises. Effective medication prevents this too. An infrared camera provides non-contact images of the changes. Researchers can use these images to determine how reliable and effective anti-allergic agents are.

8 Jul 2004

Most over-the-counter cough medications are no better than non-medicated syrup

A Penn State College of Medicine study has shown that many over-the-counter cough medicines are no better than non-medicated syrup for nighttime cough and sleep quality in children with upper respiratory tract infections.

6 Jul 2004

62 percent of frequent antihistamine users did not test positive for allergies

A new study in the current issue of Journal of Managed Care Pharmacy concludes that 62 percent of frequent antihistamine users did not test positive for allergies.

28 Jun 2004

Higher generic drug use in 2003 slowed the rising cost per prescription to a 7.9% increase

Generic drug use increased to a record 48% among Express Scripts' 50 million members during 2003, spurred by the use of several prominent new generics, fluoxetine, omeprazole and lisinopril.

9 Jun 2004

Microbes in your gut could be cause of allergies

Allergies making your life miserable? Tired of popping antihistamines like candy? Can't go anywhere without your inhaler? The real problem may not be your stuffed-up head. It could be the microbes in your gut.

1 Jun 2004

Antibiotics could be the cause of many allergies

27 May 2004

Brain cells containing the chemical histamine are critical for waking

A study by scientists with the Veterans Affairs' Neurobiology Research Laboratory and UCLA Neuropsychiatric Institute shows that brain cells containing the chemical histamine are critical for waking.

27 May 2004

Increases in co-payments may reduce the use of medications

Significant increases in co-payments may reduce the use of medications and raise concern about adverse health consequences, according to a study published in the May 19 issue of the Journal of the American Medical Association (JAMA).

22 May 2004

New practice guidelines for treating fluid in the ears

Most toddlers and preschoolers will be diagnosed with fluid in their middle ears--or otitis media with effusion (OME)--at some time before school age.

3 May 2004

Desensitization Useful for Allergy to Life-Saving Drug

When patients with life-threatening bacterial infections are allergic to antibiotics, drug desensitization may be an option when no other alternative exists according to a report published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).

21 Apr 2004

FDA approves new chewable formulation of Zyrtec® aimed at young allergy sufferers

Pfizer Inc and UCB Pharma today announced the approval of a new chewable formulation of Zyrtec® (cetirizine HCl) for the treatment of seasonal and perennial allergic rhinitis (inflammation of the nasal passages) and chronic idiopathic urticaria (itching and hives of unknown causes) in children aged two years and older. The approval by the US Food and Drug Administration makes Zyrtec the first and only prescription antihistamine available in both syrup and chewable form.

22 Mar 2004

Forward step in treatment of Allergic Rhinitis

Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company’s lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.